Delimotecan
Alternative Names: MEN 4901; T-0128Latest Information Update: 04 Nov 2017
At a glance
- Originator Tanabe Seiyaku
- Developer Menarini; Tanabe Seiyaku
- Class Antineoplastics; Camptothecins
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Cancer in European Union (IV, Infusion)
- 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
- 05 Sep 2007 Delimotecan is still in phase I trials for Cancer in the European Union